Table 7: Impact of Advanced Access Implementation on Disease-Specific Clinical Outcomes^a.

Study	Results
Subramanian et al (28)	OA clinic patients had a significant decrease in mean HbA1c, but a significant increase in mean SBP compared to non-OA clinic patients. There was no difference in change in LDL-C between OA and non-OA clinic patients Mean difference OA to non-OA clinics: HbA1c (%): –0.12 (95% CI, –0.21, –0.03) SBP (mm Hg): 6.4 (95% CI, 5.4, 7.5) LDL-C (mg/dL): –0.2 (95% CI, –2.0, 1.5)
Sperl-Hillen et al (25)	The percentage of patients with HbA1c < 7% increased significantly between the pre- and post-implementation periods, from 44.4% to 52.3% (P < 0.001)b The percentage of patients with LDL-C < 100 mg/dL increased significantly between the pre- and post-implementation periods, from 29.8% to 38.7% (P < 0.001)b
Gladstone et al (29)	Mean HbA1c decreased nonsignificantly between the pre- and post-implementation periods, from 7.2% to 7.1% (P = 0.17) Mean LDL-C decreased slightly but significantly between the pre- and post-implementation periods, from 2.7 mmol/L to 2.6 mmol/L (P = 0.04)

Abbreviations: CI, confidence interval; HbA_1c, hemoglobin A_1c; LDL-C, low-density lipoprotein cholesterol; OA, open access; SBP, systolic blood pressure.

^aThe table is ordered to reflect the quality of the included studies.

^bUtilization rates were adjusted for age, sex, and modified Charlson score.